-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Novel Therapies upon Failure of HMA + Venetoclax

Program: Education Program
Session: What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, real-world evidence, Therapies, therapy sequence
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Alison R. Walker, MD, MPH, MBA

H.Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Disclosures: No relevant conflicts of interest to declare.

OffLabel Disclosure:

See more of: What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?
See more of: Education Program
<< Previous Presentation | Next Presentation